Since only 8.9% of unselected NSCLC patients responded to EGFR TKI [24], several studies have tried to find prognostic and predictive biomarkers of sensitivity or resistance to anti-EGFR agents. This evidence concerns the gene EGFR and non-small cell lung carcinoma.